Originally published by our sister publication Pharmacy Practice News
Glucarpidase (Voraxaze, SERB Pharmaceuticals) significantly improves kidney recovery in patients experiencing nephrotoxicity caused by methotrexate, according to a new study from researchers at Brigham and Women’s Hospital (BWH) analyzing data from more than 700 patients across 28 U.S. cancer centers.
Glucarpidase has been approved by the FDA for the treatment of methotrexate-induced toxicity since 2012, but